What is LOPJLB’s current signal on LYEL?

LOPJLB’s latest quantitative signal on Lyell Immunopharma, Inc. (LYEL) is BUY in a RECOVERY regime. Signals are updated daily.

What market regime is LYEL in?

Lyell Immunopharma, Inc. (LYEL) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Lyell Immunopharma, Inc. (LYEL) do?

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The companyâs lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and…

Where is Lyell Immunopharma, Inc. based / listed?

Lyell Immunopharma, Inc. is based in US, listed on NASDAQ.

Lyell Immunopharma, Inc. (LYEL)

Healthcare · Biotechnology · NASDAQ · US

$14.74-5.09%Close

BUYRECOVERY · day 18

[SCORES & PROFILE]

FUND: 0
VALUE: 3
GROWTH: 2
GARP: 2
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-55.0%

REV YoY-

ROE-91.6%

EPS YoY-

ROA-79.9%

GROSS

-8537

-711330

NET

-920285

[VALUATION]

P/E TTM-0.92

P/E FWD-

SECTOR PE22.66

INDUSTRY PE17.07

P/B1.47

P/FCF-

EV/EBITDA-1.36

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E15.80

ALTMAN Z-

CURR RATIO5.36

ND/EBITDA-

BETA-0.07

Lyell Immunopharma, Inc. (LYEL)

Key stats

Sector peers

Industry peers

Prediction markets

FUNDAMENTALS

Company news